Tolera Therapeutics develops immunotherapeutics with a focus on the transplantation, autoimmune and oncology markets. Its lead clinical candidate is TOL101, a therapeutic monoclonal antibody intended for prevention of acute organ rejection. The company is preparing to advance TOL101 into Phase 3 clinical testing and plans to submit a Special Protocol Assessment (SPA) with the U.S. FDA. Tolera builds on research conducted at the University of Kentucky and the Cleveland Clinic. Led by CEO John Puisis, the company is commercializing its monoclonal antibody technology for the transplantation market. In October 2012 Tolera closed a financing round to fund its Phase 3 preparations.

Total raised

$6M

Funding rounds

1

Latest round

Series B

Latest activity

Oct 2012